Disc Medicine, Inc. $IRON Position Lowered by Bain Capital Life Sciences Investors LLC

Bain Capital Life Sciences Investors LLC decreased its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 40.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 583,500 shares of the company’s stock after selling 400,000 shares during the quarter. Disc Medicine accounts for approximately 3.9% of Bain Capital Life Sciences Investors LLC’s holdings, making the stock its 8th biggest position. Bain Capital Life Sciences Investors LLC owned approximately 1.68% of Disc Medicine worth $30,902,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in IRON. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Disc Medicine by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock worth $71,000 after acquiring an additional 181 shares during the period. Ameritas Investment Partners Inc. grew its position in Disc Medicine by 8.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after purchasing an additional 206 shares during the period. HighVista Strategies LLC grew its position in Disc Medicine by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 6,733 shares of the company’s stock worth $357,000 after purchasing an additional 275 shares during the period. Police & Firemen s Retirement System of New Jersey raised its stake in Disc Medicine by 12.3% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,490 shares of the company’s stock valued at $291,000 after buying an additional 600 shares during the last quarter. Finally, CWM LLC lifted its holdings in shares of Disc Medicine by 213.5% during the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after buying an additional 711 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Morgan Stanley lifted their price objective on Disc Medicine from $90.00 to $115.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, October 8th. Truist Financial upped their price target on shares of Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Cantor Fitzgerald raised their price objective on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a report on Friday, October 17th. Finally, Wedbush boosted their target price on shares of Disc Medicine from $90.00 to $110.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus price target of $120.00.

Disc Medicine Stock Down 1.9%

IRON stock opened at $91.85 on Friday. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $99.50. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The stock has a market cap of $3.47 billion, a P/E ratio of -17.17 and a beta of 0.87. The business’s 50-day moving average price is $86.06 and its 200-day moving average price is $67.28.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, equities research analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insider Buying and Selling

In other news, Director Kevin Bitterman sold 71,961 shares of the stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $70.58, for a total value of $5,079,007.38. Following the completion of the sale, the director directly owned 500,621 shares of the company’s stock, valued at $35,333,830.18. This represents a 12.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 30,000 shares of the company’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $84.70, for a total transaction of $2,541,000.00. Following the completion of the transaction, the chief operating officer directly owned 40,555 shares of the company’s stock, valued at $3,435,008.50. This represents a 42.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 213,585 shares of company stock valued at $16,898,513. Company insiders own 3.64% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.